Thank you!
Your support is sustaining the future of local news in our communities.

Omicron, surely that’s enough

What have the scientific, pharmaceutical, and medical communities done to stifle SARS-CoV-2 infections? There are currently 18 advanced trials of different vaccines, 64 possible new treatments, and 23 potential or approved anti-viral drugs.

The mRNA vaccines from Pfizer and Moderna provide robust protection. (The mRNA technology is being expanded to HIV, malaria, and other diseases for which conventional vaccines have failed.) mRNA vaccines are expensive and need to be shipped frozen. Lower income countries require an effective vaccine that is inexpensive, survives at higher temperature and can be made locally.  Corbevax, created at Baylor College of Medicine, fits these criteria and is currently being made in hundreds of millions of doses in India. Other vaccines (Novovax) produce antibodies to viral proteins in addition to the Spike protein. The Novovax vaccine contains no genetic material.

Beyond vaccines there are 64 new treatments in development that block or slow infection or some of its consequences, like inflammation. Inflammation makes blood vessels leaky; defensive cells, which rush to the site of infection, squeeze out of the circulation, and infiltrate the lungs. They fill air sacs with dead neutrophils, eosinophils, and fluid, making the patient struggle to breathe.  In addition to the inflammatory reaction, when these cells die they release digestive enzymes that can do terrible damage to the lungs or other infected tissues. The use of steroids to inhibit inflammation was a critical early discovery. According to a review I read recently, it is still the best early intervention. Most viruses have means to inhibit a host’s immune system:  some inhibit interferon synthesis, a critical mobilizer of the immune response; SARS-CoV-2 inhibits the production of Natural Killer cells, which recognize infected lung cells and kill them. The more we know about these mechanisms the better off we will be.

There are currently 23 antivirals approved or in testing, including Merck’s Molnupiravir and Pfizer’s Paxlovid, but others have Emergency Use Authorizations as well. Paxlovid, if taken within 5 days of the onset of symptoms, blocks disease progression and keeps 90% of patients from hospitalization.  As a result, our hospitals are able to function, saving money, reducing misery and increasing morale.  Vaccinated and boosted people usually have a short illness unless they have other complications and may not need these therapeutics. But for those who do, or are unvaccinated the drugs are becoming available in pharmacies.

My friend, Jonathan Sanoff, keeps track of these things. He told me about a site called the Therapeutics Locator, which The Assistant Secretary for Preparedness and Response at The Department of Health and Human Services and her staff have prepared. The Assistant Secretary is Rear Admiral Rachel L. Levine, MD. The site tells potential patients where to find these drugs, whether they are in Puerto Rico or Alaska. For skeptics, the site also includes the number of doses on hand at each site and the total made so far, as well as information on each drug. As new therapies come online, they will appear on the Therapeutics Locator. There are currently seven drugs and monoclonal antibodies on the site. The Asst Secretary and her staff do not get much credit, but they should. See: www.covid-19-therapeutics-locator-dhhs.hub.arcgis.com/.

It is important to have many anti-viral drugs, and I was surprised to learn that 23 are still in late clinicals trials. We learned from HIV therapy that an RNA virus can develop resistance to a single drug but cannot evolve resistance to three drugs and is why the number 23 is a pleasant surprise. An even better surprise is, some of these drugs inhibit other RNA viruses, including Zika and Ebola.

Nothing in science or medicine must work, no matter how clever the idea. We should not be surprised that 26 vaccines failed, 92 treatments did not pass muster, and 54 antivirals did not inhibit SARS-CoV-2.  These results on therapies in the development pipeline have been collected by Heidi Ledford, one of Nature Magazine’s senior reporters (Nature, March 3, 2022). I am grateful to her. In that context, the March 11 issue of Science, the flagship publication of the American Academy of Sciences, contains a detailed comparison and analysis of these treatments and ideas on what we need to prepare for the next epidemic. Pandemics are too large a subject to cover everything — we have left out the value of logistics and convincing people to take vaccines, not to mention long Covid, but people are studying these challenges. The combination of basic science, private industry, and public health services have done well, although praise sounds hollow when millions have died.

What to do? Get vaccinated and boosted. When new boosters designed to attack SARS-CoV-2 or its variants appear, get those too. Even with the vaccine, you may get mild disease, but the name of the game is to prevent progress to serious disease and hospitalization. The new drugs offer reassurance. In places where the virus and infection are in decline, it is time to resume normal life.  Or at least that is my plan.

 

Richard Kessin is Emeritus Professor of Pathology and Cell Biology at the Columbia University Irving Medical Center. Reach him at Richard.Kessin@gmail.com. His website contains more information: RichardKessin.com.

 

 

       

             

 

The views expressed here are not necessarily those of The Lakeville Journal and The Journal does not support or oppose candidates for public office.

Latest News

Residents tear down Patriot Front signs in North Canaan and Falls Village

A Patriot Front sign hangs in front of the Canfield Building on Main Street in North Canaan on Wednesday, Nov. 11. The sign was removed later that day.

Madi Long

NORTH CANAAN — Residents in North Canaan and Falls Village have taken down signs bearing the name Patriot Front, which the Southern Poverty Law Center classifies as a white nationalist hate group. Connecticut State Police said they referred two incidents to hate crimes investigators.

On Nov. 2, a Troop B sergeant spotted a sign on a utility pole near Route 7 and North Elm Street. State police contacted the utility company, which took down the sign.

Keep ReadingShow less

Sharon revisits speed cameras, weighs humps

Sharon revisits speed cameras, weighs humps
A speed camera in Washington, Conn. Sharon selectmen have discussed installing similar cameras.
Alec Linden

SHARON — A group of more than 20 residents who live along Jewett Hill Road has petitioned the town to install speed humps on their roadway. Jewett Hill Road runs less than a mile between Calkinstown Road and Jackson Hill Road.

The petition prompted a broader discussion about speeding at the Sharon Board of Selectmen meeting on Nov. 10. First Selectman Casey Flanagan said he plans to revive an earlier proposal to use speed cameras on town roads and resume talks with an installation company.

Keep ReadingShow less
North Canaan recovers $15,000 in nip fees sent to New Canaan
North Canaan Town Hall
File photo

NORTH CANAAN — The town has recovered $15,000 in lost revenue from a surcharge on miniature liquor bottles after Treasurer Melanie Neely discovered that the money had mistakenly been sent to New Canaan.

First Selectman Jesse Bunce announced the recovery at the Nov. 9 Board of Selectmen meeting, drawing a round of applause. Bunce investigated the discrepancy after Neely brought it to his attention.

Keep ReadingShow less
google preferred source

Want more of our stories on Google? Click here to make us a Preferred Source.

Northwest Corner veterans help one another get care

Couch-Pipa VFW Post 6851

Patrick Stachniak

NORTH CANAAN — As the flags from Veterans Day parades are furled and the public tributes fade, veterans in Connecticut’s rural Northwest Corner still face the quieter work of finding care and talking about the pain and anguish they brought home.

Those challenges can become more acute as winter and the holidays approach, said Keith Appleton, an Army veteran and licensed master social worker at Mountainside Treatment Center.

Keep ReadingShow less
Northwest Corner honors veterans at schools and memorials

Local veterans salute during the Veterans Day ceremony in Kent.

Ruth Epstein

NORTHWEST CORNER — Students, veterans and neighbors across the Northwest Corner marked Veterans Day with school assemblies and ceremonies at town memorials.

Salisbury Central School held its assembly Tuesday, Nov. 10. Schools in Falls Village, Cornwall, Sharon and Kent also observed the holiday.

Keep ReadingShow less
Salisbury’s median home sale price rises 5% to $920,000

This four-bedroom house at 175 Main St. in Salisbury sold for $990,000 on Sept. 30. It sold for $1,025,000 in January 2022.

Christine Bates

SALISBURY — The median sale price of a single-family home in Salisbury rose to $920,000 for the 12 months ended Oct. 31, up 5.1% from $875,000 a year earlier and 6.4% from $865,000 for the same period in 2024. The figures exclude condominiums.

The rolling 12-month median peaked at $1.35 million in May 2025 and fell to $775,000 at the start of 2026. It has remained above $900,000 since July.

Keep ReadingShow less
google preferred source

Want more of our stories on Google? Click here to make us a Preferred Source.

google preferred source

Want more of our stories on Google? Click here to make us a Preferred Source.